Stocks in Action USA: Certara (CERT), D-Wave Quantum, Bank of New York

Certara (CERT) – The specialist in model-based drug development reports solid growth with preliminary figures! Certara, a leading provider of model-based drug development, recorded an 8% increase in revenue for 2024, totaling $384.4 million. The software business experienced particularly dynamic growth, rising 18% to $155 million, while service revenues increased by 3% to $229.4 million. In the fourth quarter, total revenue grew by 13% to $99.7 million, with a particularly strong increase of 24% in the software sector. The acquisition of Chemaxon...